TGFB1 and glioblastoma: The commercially available TGF-β inhibitors, TGF-β RI kinase inhibitor V and LY 2109761, also decreased SBE-4 luciferase activity in established GBM lines and a GIC line (Supplementary Figure 3B and 3C).